Linked infacebooktwitteryoutube
Datar Cancer Genetics

Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Limited

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Alzheimer

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE plc

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

Datar Cancer Genetics

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Pancreatic Cancer and Genomics: Revisiting Advances and Challenges

NextEdge Admin
24 Nov 2024
4 min 43 sec
0
Genomics,Insight

The intersection of pancreatic cancer and genomics has led to significant advancements in understanding this aggressive disease. Here’s an updated look at the relationship between genomics and pancreatic cancer:


1. Genomic Alterations in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is marked by a range of genomic abnormalities:

  • KRAS Mutations: Nearly all PDACs (90-95%) harbor mutations in the KRAS gene, making it a hallmark driver mutation.
  • Tumor Suppressors:
    • TP53 mutations occur in approximately 70-75% of cases.
    • CDKN2A (p16) and SMAD4 are frequently inactivated, contributing to tumor progression.
  • Other Drivers:
    • Alterations in genes like ARID1A, RNF43, and DNA repair genes (e.g., BRCA1/BRCA2, PALB2) have been observed.

2. Role of Genomics in Early Detection

  • Liquid Biopsies: Circulating tumor DNA (ctDNA) and tumor-derived exosomes provide opportunities for early detection of pancreatic cancer by identifying specific mutations or methylation patterns.
  • Polygenic Risk Scores (PRS): For individuals with familial pancreatic cancer, PRS integrates common genetic variants to assess cancer susceptibility.

3. Genomic Subtypes of PDAC

Genomic profiling has revealed distinct molecular subtypes of pancreatic cancer, aiding in personalized treatment strategies:

  • Classical: Characterized by epithelial-like features and a better prognosis.
  • Basal-like: Associated with more aggressive behavior and resistance to therapy.
  • Mutational Signatures:
    • Mismatch repair deficiency (MMRd) and microsatellite instability (MSI) point to immunotherapy opportunities.
    • Defects in homologous recombination (e.g., BRCA mutations) predict sensitivity to platinum-based chemotherapies and PARP inhibitors.

4. Implications for Treatment

  • Targeted Therapy: Genomic insights have paved the way for:
    • KRAS G12C inhibitors (though efficacy in PDAC remains under investigation).
    • Therapies targeting other KRAS mutations (e.g., G12D or G12V) are in development.
  • Immunotherapy:
    • Although PDAC has been largely refractory to immune checkpoint inhibitors, MSI-high tumors or those with high tumor mutational burden (TMB) respond better.
  • Synthetic Lethality:
    • PARP inhibitors like olaparib are effective in patients with BRCA or PALB2 mutations.

5. Emerging Research Areas

  • Organoid Models: Derived from patients, these models enable functional genomics and drug screening for personalized therapy.
  • Single-Cell Sequencing: This technology reveals tumor heterogeneity, immune microenvironment interactions, and resistance mechanisms.
  • Epigenomics: Altered DNA methylation and histone modifications are emerging as therapeutic targets.

6. Challenges and Future Directions

  • Tumor Heterogeneity: Intratumoral and intertumoral diversity complicates the development of universal biomarkers and therapies.
  • Early Detection Barriers: Reliable biomarkers for detecting pancreatic cancer at an early, treatable stage remain elusive.
  • Therapeutic Resistance: Genomic plasticity allows tumors to adapt and resist targeted therapies, underscoring the need for combination treatments.